Evidence map›Paper›PMID 36075878›Full record

ReviewCancer communications (London, England)2022

Non-small cell lung cancer in China.

Peixin Chen, Yunhuan Liu, Yaokai Wen, Caicun Zhou

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer communications (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07486648 (The Safety and Efficacy of Osimertinib Plus Capivasertib in EGFRm Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 437 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
437citing papers in PubMed, 4 pooled it
86.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07486648 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Safety and Efficacy of Osimertinib Plus Capivasertib in EGFRm Advanced Non-small Cell Lung Cancer (NSCLC) Participants With PIK3CA/AKT1/PTEN Alterations Who Had Progressed on First-line Osimertinib Monotherapy or Plus Chemotherapy: a First-in-human, Phase Ib/Ⅱa Study (PRECISION)

TypeinterventionalSponsorShanxi Province Cancer HospitalRan2026 to 2028Enrolled53ConditionsLung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Advanced Non-small-cell Lung CancerArmsCapivasertib in combination with Osimertinib
3 · Its place in the literature

Who cites it

437 citing papers in PubMed, 4 syntheses or guidelines pooled it, 614 citations in OpenAlex.

  1. Pooled it
  2. [Clinical Progress and Prospects of Antibody-drug Conjugates in Advanced NSCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

377 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Peixin ChenSchool of Medicine, Tongji University, Shanghai, 200092, P. R. China.ORCID 0000-0002-4192-8396
Yunhuan LiuDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai, 200040, P. R. China.
Yaokai WenSchool of Medicine, Tongji University, Shanghai, 200092, P. R. China.
Caicun ZhouSchool of Medicine, Tongji University, Shanghai, 200092, P. R. China.
Tongji University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early-stage non-small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population-based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor monotherapy and PD-1/PD-L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorclinical guidelinesclinical trialsepidermal growth factor receptor (EGFR) mutationimmunotherapynon-small cell lung cancerprogrammed cell death protein 1 (PD-1)programmed death-ligand 1 (PD-L1)screeningtargeted therapy

Identifiers

PMID36075878
PMCPMC9558689
OpenAlexW4295079305

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.